
Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
BASEL, Switzerland and SAN DIEGO, June 15, 2026 /PRNewswire/ — Lonza and Antharis Therapeutics, Inc., a biopharmaceutical company developing next-generation antibody-based therapeutics for oncology, today announced an exclusive,
























